HC Wainwright Reaffirms “Buy” Rating for Valneva (NASDAQ:VALN)

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $17.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 185.23% from the company’s current price.

Separately, Guggenheim decreased their target price on Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 24th.

Valneva Stock Performance

Shares of VALN traded down $0.08 during mid-day trading on Wednesday, hitting $5.96. The stock had a trading volume of 2,381,784 shares, compared to its average volume of 36,285. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $484.32 million, a PE ratio of -45.77 and a beta of 1.85. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50. The company’s fifty day simple moving average is $6.90 and its two-hundred day simple moving average is $5.61.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The business had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. On average, equities analysts expect that Valneva will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Valneva

Several hedge funds and other institutional investors have recently modified their holdings of VALN. GAMMA Investing LLC acquired a new position in Valneva during the 1st quarter valued at about $94,000. ABC Arbitrage SA acquired a new position in shares of Valneva during the fourth quarter worth approximately $84,000. Finally, Wells Fargo & Company MN grew its holdings in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after buying an additional 30,859 shares in the last quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.